These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 36258299)
1. Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system. He L; Zhong J; Li G; Lin Z; Zhao P; Yang C; Wang H; Zhang Y; Yang X; Wang Z J Med Virol; 2023 Jan; 95(1):e28237. PubMed ID: 36258299 [TBL] [Abstract][Full Text] [Related]
2. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648 [TBL] [Abstract][Full Text] [Related]
3. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM Front Immunol; 2021; 12():791764. PubMed ID: 34868082 [TBL] [Abstract][Full Text] [Related]
4. Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection. Kim DH; Lee J; Youk S; Jeong JH; Lee DY; Ju HS; Youn HN; Kim JC; Park SB; Park JE; Kim JY; Kim TH; Lee SH; Lee H; Mouhamed Abdallah Amal Abdal L; Lee DH; Park PG; Hong KJ; Song CS Vaccine; 2023 Jul; 41(33):4787-4797. PubMed ID: 37355454 [TBL] [Abstract][Full Text] [Related]
6. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization. Zhang QY; Zhang HQ; Zhang YN; Zhang ZR; Li XD; Hao MC; Zhang Y; Li JQ; Hu YY; Chen XL; Wang J; Shi YJ; Deng CL; Chen JJ; Ye HQ; Zhang B Antiviral Res; 2023 Dec; 220():105757. PubMed ID: 37984567 [TBL] [Abstract][Full Text] [Related]
7. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571 [TBL] [Abstract][Full Text] [Related]
8. Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters. de Swart RL; de Leeuw OS; Oreshkova N; Gerhards NM; Albulescu IC; Vreman S; Gonzales JL; Maas R; van Kuppeveld FJM; Soema P; Bosch BJ; Peeters BPH Vaccine; 2022 Aug; 40(33):4676-4681. PubMed ID: 35820941 [TBL] [Abstract][Full Text] [Related]
9. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P EBioMedicine; 2020 Dec; 62():103132. PubMed ID: 33232870 [TBL] [Abstract][Full Text] [Related]
10. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins. Cacciottolo M; Nice JB; Li Y; LeClaire MJ; Twaddle R; Mora CL; Adachi SY; Chin ER; Young M; Angeles J; Elliott K; Sun M Microbiol Spectr; 2023 Jun; 11(3):e0050323. PubMed ID: 37093009 [TBL] [Abstract][Full Text] [Related]
11. A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. Shirvani E; Paldurai A; Manoharan VK; Varghese BP; Samal SK Sci Rep; 2018 Aug; 8(1):11951. PubMed ID: 30097608 [TBL] [Abstract][Full Text] [Related]
12. A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. Martins M; do Nascimento GM; Conforti A; Noll JCG; Impellizeri JA; Sanchez E; Wagner B; Lione L; Salvatori E; Pinto E; Compagnone M; Viscount B; Hayward J; Shorrock C; Aurisicchio L; Diel DG Arch Virol; 2023 Mar; 168(4):124. PubMed ID: 36988739 [TBL] [Abstract][Full Text] [Related]
13. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873 [TBL] [Abstract][Full Text] [Related]
14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
15. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters. de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096 [TBL] [Abstract][Full Text] [Related]
16. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927 [TBL] [Abstract][Full Text] [Related]
17. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
19. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
20. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens. Kanabagatte Basavarajappa M; Kumar S; Khattar SK; Gebreluul GT; Paldurai A; Samal SK Vaccine; 2014 Jun; 32(28):3555-63. PubMed ID: 24793943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]